TABLE 2.
League tables for (a) Successful feeding rate; (b) Postpyloric intubation success; (c) GRV; (d) Treatment-related adverse effect.
| a. Successful feeding rate (OR, 95% CI) | ||||
|---|---|---|---|---|
| Combine | 3.03 (1.90, 4.83) | 0.62 (0.41, 0.94) | ||
| 0.33 (0.21, 0.53) | Erythromycin | 0.20 (0.13, 0.33) | ||
| 1.61 (1.06, 2.45) | 4.89 (3.01, 7.93) | Metoclopramide | ||
| b. Postpyloric intubation success (OR, 95% CI) | ||||
| ERY | 0.71 (0.05, 10.91) | 1.69 (0.31, 9.10) | 1.00 (0.31, 3.24) | 0.41 (0.10, 1.69) |
| 1.41 (0.09, 21.69) | Blankcontrol | 2.38 (0.11, 51.54) | 1.41 (0.12, 16.64) | 0.58 (0.03, 11.14) |
| 0.59 (0.11, 3.19) | 0.42 (0.02, 9.09) | Combine | 0.59 (0.09, 3.71) | 0.24 (0.03, 2.07) |
| 1.00 (0.31, 3.24) | 0.71 (0.06, 8.36) | 1.69 (0.27, 10.57) | Metoclopramide | 0.41 (0.08, 2.08) |
| 2.42 (0.59, 9.90) | 1.72 (0.09, 32.78) | 4.09 (0.48, 34.57) | 2.42 (0.48, 12.19) | Placebo |
| c. GRV (MD, 95% CI) | ||||
| ERY | −11.28 (−206.68, 184.12) | −65.67 (−192.97, 61.63) | ||
| 11.28 (−184.12, 206.68) | Combine | −54.39 (−249.86, 141.08) | ||
| 65.67 (−61.63, 192.97) | 54.39 (−141.08, 249.86) | Metoclopramide | ||
| d. Any reported adverse events (OR, 95% CI) | ||||
| ERY | 0.53 (0.05, 6.20) | 1.45 (0.99, 2.14) | 0.70 (0.51, 0.96) | 0.38 (0.08, 1.81) |
| 1.88 (0.16, 21.94) | Blankcontrol | 2.73 (0.23, 32.51) | 1.31 (0.11, 15.20) | 0.72 (0.04, 13.11) |
| 0.69 (0.47, 1.01) | 0.37 (0.03, 4.36) | Combine | 0.48 (0.31, 0.74) | 0.26 (0.05, 1.30) |
| 1.43 (1.04, 1.97) | 0.76 (0.07, 8.81) | 2.08 (1.36, 3.18) | Metoclopramide | 0.55 (0.12, 2.63) |
| 2.60 (0.55, 12.23) | 1.38 (0.08, 25.08) | 3.78 (0.77, 18.52) | 1.82 (0.38, 8.68) | Placebo |
For each league table, estimates in the lower triangle represent the odds ratio (or mean difference) for the row treatment compared with the column treatment; estimates in the upper triangle represent the column treatment compared with the row treatment. For odds ratios, values < 1 favor the column treatment, values > 1 favor the row treatment.